al'Absi M, Hatsukami D, Davis GL, and Wittmers LE. Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug and Alcohol Dependence. 2004;73(3):267-278.

Carmella SG, Le KA, and Hecht SS. Improved method for determination of 1-hydroxypyrene in human urine. Cancer Epidemiology, Biomarkers and Prevention. 2004;13(7):1261-1264.

Hatsukami DK, Henningfield JE, and Kotlyar M. Harm reduction approaches to reducing tobacco-related mortality. Annual Review of Public. 2004;25:377-395.

Hatsukami DK, Lemmonds C, and Tomar SL. Smokeless tobacco use: harm reduction or induction approach? Preventive Medicine. 2004;38(3):309-317.

Hatsukami DK, Lemmonds C, Zhang Y, Murphy SE, Le C, Carmella SG, and Hecht SS. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. Journal of the National Cancer Institute. 2004;96(11):844-852.

Hecht SS. Carcinogen derived biomarkers: applications in studies of human exposure to secondhand tobacco smoke. Tobacco Control. 2004;13 Suppl 1:i48-56.

Hecht SS. Tobacco smoke carcinogens: human uptake and DNA interactions. In P. Boyle, N. Gray, J. Henningfield, J. Seffrin & W. Zatonski (Eds.), Tobacco: The Public Health Disaster of the Twentieth Century: Oxford University Press, 2004.

Hecht SS, Carmella SG, Le KA, Murphy SE, Li YS, Le C, Jensen J, and Hatsukami DK. Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. Cancer Epidemiology, Biomarkers and Prevention. 2004;13(5):834-842.

Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, Roe MR, Puumala SS, Li YS, Le C, Jensen J, and Hatsukami DK. Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. Journal of the National Cancer Institute. 2004;96(2):107-115.

Hughes JR, Hecht SS, Carmella SG, Murphy SE, and Callas P. Smoking behaviour and toxin exposure during six weeks use of a potential reduced exposure product: Omni. Tobacco Control. 2004;13(2), 175-179.

Joseph AM, Hennrikus D, Thoele MJ, Krueger R, and Hatsukami D. Community tobacco control leaders' perceptions of harm reduction. Tobacco Control. 2004;13(2), 108-113.

Lemmonds CA, Mooney M, Reich B, and Hatsukami D. Characteristics of cigarette smokers seeking treatment for cessation versus reduction. Addictive Behaviors. 2004;29(2), 357-364.

LeSage MG, Burroughs D, Dufek M, Keyler DE, and Pentel PR. Reinstatement of nicotine self-administration in rats by presentation of nicotine-paired stimuli, but not nicotine priming. Pharmacology, Biochemistry and Behavior. 2004;79(3):507-513.

Mooney M, White T, and Hatsukami D. The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials. Addictive Behaviors. 2004;29(4):673-684.

Murphy SE, Link CA, Jensen J, Le C, Puumala SS, Hecht SS, Carmella SG, Losey L, and Hatsukami DK. A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. Cancer Epidemiology, Biomarkers and Prevention. 2004;13(10):1617-1623.

Pentel PR. Vaccines and depot medications for drug addiction: Rationale, mechanisms of action, and treatment implications. In H. Harwood & T. Myers (Eds.), New Treatments for Addiction: Behavioral, Ethical, Legal and Social Questions. Washington, DC: National Academies Press, Institute of Medicine Report, 2004.